Concerns about how to use established minimal residual disease monitoring in the treatment of NPM1-mutant acute myeloid leukaemia (AML) following reduced intensity chemotherapy protocols for AML given as a result of the COVID-19 pandemic.

Farah, Nadine; Burt, Richard; Ibrahim, Amr R; Baker, Robert; Kottaridis, Panagiotis D

Farah, Nadine; Burt, Richard; Ibrahim, Amr R; Baker, Robert; Kottaridis, Panagiotis D.

Farah N; HCA Healthcare at UCH, University College Hospitals NHS Foundation Trust, London, UK.
Burt R; UCL Cancer Institute, UCL, London, UK.
Ibrahim AR; HCA Healthcare at UCH, University College Hospitals NHS Foundation Trust, London, UK.
Baker R; UCL Cancer Institute, UCL, London, UK.
Kottaridis PD; Department of Haematology, University College Hospitals NHS Foundation Trust, London, UK.

Br J Haematol ; 190(4): e208-e210, 2020 08.

Article in English | MEDLINE | ID: covidwho-998784

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/administration & dosage; COVID-19 Drug Treatment; COVID-19; Leukemia, Myeloid, Acute; Mutation; Nuclear Proteins/genetics; SARS-CoV-2; Adult; COVID-19/blood; COVID-19/genetics; Cytarabine/administration & dosage; Daunorubicin/administration & dosage; Gemtuzumab/administration & dosage; Humans; Leukemia, Myeloid, Acute/blood; Leukemia, Myeloid, Acute/drug therapy; Leukemia, Myeloid, Acute/genetics; Male; Neoplasm, Residual; Nucleophosmin

Keywords

AML; MRD; acute leukaemia; molecular genetics; molecular haematology

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Nuclear Proteins / Leukemia, Myeloid, Acute / Antineoplastic Combined Chemotherapy Protocols / SARS-CoV-2 / COVID-19 / COVID-19 Drug Treatment / Mutation Type of study: Case report Limits: Adult / Humans / Male Language: English Journal: Br J Haematol Year: 2020 Document Type: Article Affiliation country: Bjh.16985

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google